Theraclone Sciences

company

About

Theraclone Sciences is a biotech company developing novel therapeutic antibodies for the treatment of infectious diseases and inflammation.

  • 11 - 50

Details

Last Funding Type
Series B
Last Funding Money Raised
$8M
Industries
Biotechnology,Health Care,Medical,Therapeutics
Founded date
Jan 1, 2004
Number Of Employee
11 - 50
Operating Status
Active

Theraclone Sciences (formerly Spaltudaq) is a Seattle-based discovery-stage biotech focused on the development of novel therapeutic antibodies for the treatment of infectious disease and inflammation. The company's technology harnesses the power of the human immune system to identify naturally evolved monoclonal antibodies from the blood cells of immunologically relevant human subjects. Recombinant human monoclonal antibodies can be rapidly obtained using our discovery platform and scaled for large-scale industrial production. Such antibody drug candidates may be uniquely important in combating disease and may have potential as therapeutic products that can be administered to a broad patient population. Theraclone is a privately held company with venture investment from ARCH Venture Partners, Canaan Partners, Healthcare Ventures, Amgen Ventures, MPM Capital, and Alexandria Real Estate Investment.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
5
$53.70M
Theraclone Sciences has raised a total of $53.70M in funding over 2 rounds. Their latest funding was raised on Mar 25, 2013 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Mar 25, 2013 Series B $8M 2 Detail
Sep 8, 2011 Series B $10.60M 1 Detail
Mar 17, 2010 Series Unknown $1.50M 1 Detail
Mar 19, 2007 Series B $29M 1 ARCH Venture Partners Detail
Mar 3, 2006 Series A $4.60M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Theraclone Sciences is funded by 2 investors. ARCH Venture Partners and Versant Ventures are the most recent investors.
Investor Name Lead Investor Funding Round
ARCH Venture Partners Series B
Versant Ventures Series B